P/E ratio for Co-Diagnostics (CODX)
P/E ratio as of April 2024 (TTM): -0.9032
According to Co-Diagnostics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.903226. At the end of 2022 the company had a P/E ratio of -5.48.
P/E ratio history for Co-Diagnostics from 2017 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -5.48 | -178.52% |
| 2021 | 6.98 | 13.28% |
| 2020 | 6.16 | -354.62% |
| 2019 | -2.42 | -18.83% |
| 2018 | -2.98 | -34.58% |
| 2017 | -4.56 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 PAVmed
PAVM | -2.07 | 128.68% | 🇺🇸 USA |
 Philips PHG | -29.6 | 3,172.65% | 🇳🇱 Netherlands |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.